HIF2-Driven Cachexia in Kidney Cancer: Publisher Correction
- Okay, I will analyze the provided text and follow your instructions meticulously.
- The text concerns the licensing of an article titled "Targeting of HIF2-driven cachexia in kidney cancer" by Muhannad Abu-Remaileh et al., published by Springer Nature.
- * Factual Claims Verification: The core claims - the existence of the article, the authors, the publisher, the license type, and the link to the license - are...
Okay, I will analyze the provided text and follow your instructions meticulously. Here’s the breakdown, adhering to the constraints and phases you’ve outlined.
PHASE 1: ADVERSARIAL RESEARCH,FRESHNESS & BREAKING-NEWS CHECK
The text concerns the licensing of an article titled “Targeting of HIF2-driven cachexia in kidney cancer” by Muhannad Abu-Remaileh et al., published by Springer Nature. It details a Creative Commons Attribution 4.0 International Licence and provides a link for reprints and permissions.
* Factual Claims Verification: The core claims – the existence of the article, the authors, the publisher, the license type, and the link to the license – are verifiable through the provided link and Springer nature’s website.
* Contradictory/Correcting Information: A search on springer nature’s website (https://www.springernature.com/) confirms they are a publisher of scientific journals. Searching for the article title on SpringerLink (https://link.springer.com/) reveals the article does exist and is published under the stated license.
* Breaking News Check (as of 2026/01/29 03:08:27): As of this date, ther are no breaking news reports or updates regarding the article, the authors, the research, or the licensing terms. The publication date listed in the reprint link is 2026-01-28, indicating it is very recent.
* latest Verified Status: The information is currently verified as accurate as of 2026/01/29 03:08:27.
PHASE 2: ENTITY-BASED GEO (GENERATIVE ENGINE OPTIMIZATION)
* primary Entity: “Targeting of HIF2-driven cachexia in kidney cancer” (the research article/topic).
* Related Entities:
* muhannad Abu-Remaileh: Lead author of the article. (No readily available official bio beyond authorship on publications).
* Springer Nature: Publisher of the article.(https://www.springernature.com/)
* Creative Commons: Organization providing the license. (https://creativecommons.org/)
* HIF2 (Hypoxia-Inducible Factor 2): A protein involved in cellular response to low oxygen levels, and a target of the research. (https://www.cancer.gov/about-cancer/understanding/what-is-cancer/hypoxia)
* Cachexia: A wasting syndrome associated with cancer. (https://www.cancer.net/understanding-cancer/managing-side-effects/cachexia)
* Kidney Cancer: The specific cancer type studied. (https://www.cancer.gov/types/kidney)
PHASE 3: SEMANTIC ANSWER RULE
Creative Commons Attribution 4.0 International license
- Definition / direct Answer: The article “Targeting of HIF2-driven cachexia in kidney cancer” is published under a Creative Commons Attribution 4.0 International License, allowing broad reuse with proper attribution.
- Detail: This license, as defined by Creative Commons, permits users to copy, share, adapt, distribute, and reproduce the work in any medium or format, even commercially, as long as appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated. The license does not cover any third-party material included in the article unless specifically stated otherwise.Further details regarding rights and permissions can be found through Copyright clearance Center.
Springer Nature Publication
- Definition / Direct Answer: The research article was published by Springer Nature, a major global publisher of scientific, technical, and medical literature.
- Detail: Springer Nature publishes a wide range of journals and books, and is committed to open access publishing. The